PLX

Protalix Biotherapeutics, Inc. (PLX) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2024. Protalix Biotherapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell expression system. The company's primary commercial products are Elelyso (for Gaucher disease) and Elfabrio (for Fabry disease). Operations are primarily conducted in Israel, with significant exposure to regional geopolitical risks.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased significantly year-over-year (61% drop in Q2, 61% drop YTD). This is primarily due to the absence of a $20.0 million regulatory milestone payment from partner Chiesi received in Q2 2023 following FDA approval of Elfabrio. License and R&D revenue dropped from $20.0 million to $0.17 million in Q2.
• Product Sales Mix: While Chiesi sales decreased by $10.0 million (due to the lack of milestone and lower inventory buildup), sales to Pfizer (Elelyso) and Brazil (Fiocruz) increased, partially offsetting the decline.
• Profitability: The company shifted from a net profit of $19.3 million in Q2 2023 to a net loss of $2.2 million in Q2 2024. Operating expenses decreased slightly, but the loss of the milestone revenue was the primary driver of the loss.
• Accounting Change: The company adopted ASU 2020-06 on January 1, 2024, simplifying the accounting for convertible notes. This resulted in a reclassification of the equity component of the notes to the liability component, increasing the carrying value of the notes by $169,000.

Outlook, Risks, and Management Commentary

• Liquidity & Debt: The company holds approximately $45.0 million in cash and short-term deposits. It has $20.42 million in 7.50% Senior Secured Convertible Notes maturing on September 1, 2024. Management believes current liquidity is sufficient to fund operations for at least 12 months, including the redemption of these notes.
• Geopolitical Risk: Operations are based in Israel. The filing highlights risks associated with the ongoing conflict involving Hamas and Hezbollah. While operations have not yet been disrupted, the company notes the potential for facility damage or supply chain interruptions.
• Pipeline Progress:
  • PRX-115 (Gout): Phase I First-in-Human trial expanded to an eighth cohort; 64 patients dosed as of June 30, 2024. Preparations for Phase II have commenced.
  • PRX-119 (NETs-related diseases): Preclinical development is ongoing.
• Commercialization: Elfabrio commercialization continues with Chiesi. The company expects revenues from Elfabrio and Elelyso to increase but notes that these may not be sufficient to fund all future R&D expenditures without additional financing.
• ATM Program: Approximately $6.4 million remains available under the 2023 Sales Agreement for potential equity raises.

Key Facts for Investor Verification

• Debt Maturity: Verify the company's ability to repay or refinance the $20.42 million convertible note due September 1, 2024, given the current cash balance of ~$45 million.
• Revenue Sustainability: Assess the trajectory of product sales (Elelyso/Elfabrio) to determine if they can replace the one-time milestone revenue that drove profitability in 2023.
• Geopolitical Exposure: Monitor the situation in Israel for any impact on manufacturing facilities in Carmiel or supply chain logistics.
• Chiesi Partnership: Track the commercial uptake of Elfabrio by Chiesi, as Protalix's future revenue is heavily tied to tiered payments based on Chiesi's sales performance.
• ATM Availability: Note that the company has limited remaining capacity ($6.4M) under its current At-The-Market offering agreement.